The acquisition brings commercial and late-stage endocrinology assets with blockbuster potential, supporting immediate and long-term revenue growth. The deal, valued at $10 billion, is expected to close in Q3 2026, pending regulatory and shareholder approvals.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.